NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Market Closed 06-05 16:00:00 EDT

4.14

+0.09

+2.22%

盘后4.10

-0.04-0.97%

19:58 EDT

High4.28	Low3.94	Vol2.03M
Open4.09	D1 Closing4.05	Amplitude8.42%
Mkt Cap149.99M	Tradable Cap138.62M	Total Shares36.23M
T/O8.28M	T/O Rate6.05%	Tradable Shares33.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":4.14,"timestamp":1780689600000,"preClose":4.05,"halted":0,"volume":2026031,"hourTrading":{"tag":"盘后","latestPrice":4.1,"preClose":4.14,"latestTime":"19:58 EDT","volume":10910,"amount":44861.7121,"timestamp":1780703916308,"change":-0.04,"changeRate":-0.009662,"amplitude":0.016908},"delay":0,"changeRate":0.02222222222222219,"floatShares":33482947,"shares":36228992,"eps":-0.966884,"marketStatus":"Market Closed","change":0.09,"latestTime":"06-05 16:00:00 EDT","open":4.09,"high":4.2761,"low":3.935,"amount":8278527.7875264995,"amplitude":0.084222,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.966884,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":4.05,"preHourTrading":{"tag":"盘前","latestPrice":4.0984,"preClose":4.05,"latestTime":"09:15 EDT","volume":3139,"amount":12906.667107,"timestamp":1780665338488,"change":0.0484,"changeRate":0.011951,"amplitude":0.036963},"postHourTrading":{"tag":"盘后","latestPrice":4.1,"preClose":4.14,"latestTime":"19:58 EDT","volume":10910,"amount":44861.7121,"timestamp":1780703916308,"change":-0.04,"changeRate":-0.009662,"amplitude":0.016908},"volumeRatio":0.9093560080296546,"impliedVol":2.4816,"impliedVolPercentile":0.9323},"requestUrl":"/m/hq/s/NRXP/wiki","defaultTab":"wiki","newsList":[{"id":"2641148249","title":"NRx notes real-world study showing IV ketamine beats nasal esketamine on depression remission, response rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148249","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641148249?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:50","pubTimestamp":1780663851,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals flagged results already presented in a peer-reviewed poster at the 2026 American Society of Clinical Psychopharmacology meeting.Real-world electronic health record analysis compared IV ketamine with intranasal esketamine in adults with treatment-resistant depression across community psychiatry clinics.IV ketamine showed higher rates of symptom improvement, response, and remission than intranasal esketamine in routine clinical care.Findings were limited by non-random treatment assignment, raising the risk that patient differences influenced outcomes.NRx highlighted the data as supportive of its IV ketamine program as it pursues a regulatory path that incorporates real-world evidence.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL43yzvR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4112","IE00BN0W2W23.USD","LU2210150020.SGD","BK4585","SG9999014013.SGD","LU2095319765.USD","NDAQ","NRXP","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014039.USD","BK4007","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641414310","title":"NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641414310","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641414310?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:50","pubTimestamp":1780663800,"startTime":"0","endTime":"0","summary":"Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307371/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-notes-presentation-by-Osmind-Inc-of-IV-Ketamine-Efficacy-vs-Nasal-esketamine-Efficacy-at-American-Society-of-Clinical-Psychopharmacology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP","BK4107","AFG","BK4117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641167726","title":"NRx Pharmaceuticals closes USD 22.3 million follow-on stock offering at USD 3.5 a share","url":"https://stock-news.laohu8.com/highlight/detail?id=2641167726","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641167726?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:12","pubTimestamp":1780607547,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals closed an underwritten follow-on offering of common stock priced at USD 3.5 a share.Gross proceeds totaled about USD 22.3 million, including full exercise of the underwriters’ option for additional shares.Net proceeds earmarked for working capital, general corporate purposes, and growth initiatives.BTIG served as lead bookrunner; Lucid Capital Markets acted as joint bookrunner.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL4zZ926:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2T93.GBP","LU0314104364.USD","BK4007","NDAQ","BK4112","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641016771","title":"NRX Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2641016771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641016771?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:12","pubTimestamp":1780607531,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA93LJWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640183562","title":"BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2640183562","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640183562?lang=en_us&edition=fundamental","pubTime":"2026-06-03 23:42","pubTimestamp":1780501359,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the RunwayWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nL6N42B103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUNR","OWL","TBN","TPL","TTI","CTMX","AADX","RJF","GPN","FDX","GME","SDOT","STLD","MDT","MLYS","OLLI","GRRR","HIMS","TGTX","YUM","FICO","REGN","XOS","RENT","LDOS","HGV","NRXP","JZ","GTLB","SMR","USAR","AXSM","MMED","KKR","GMEY","COCP","WCT","TE","BX","WDC","CETX","THO","INCY","NOTV","ARES","MX","TISI","CELC","FLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640100902","title":"BUZZ-U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics","url":"https://stock-news.laohu8.com/highlight/detail?id=2640100902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640100902?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:14","pubTimestamp":1780492449,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel DynamicsWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nL6N42B0NB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1935042488.USD","LU1989764664.SGD","IE00B3PB1722.GBP","LU0496365809.HKD","LU0211326755.USD","BK4135","LU0006306889.USD","LU1670628061.USD","USGG","LU2361044949.HKD","LU0106831901.USD","LU1057294990.SGD","IE00BGHQF631.EUR","IE00BGHQF748.EUR","LU0070302665.USD","BK4006","LU2111349929.HKD","BK4585","LU0052756011.USD","LU2089984988.USD","LU1023059063.AUD","LU0158827781.USD","BK4131","GME","BK4547","BK4602","IE0031619046.USD","IE00BVYPNV92.GBP","LU2028103732.USD","BK4607","LU0648001328.SGD","IE00BQXX3F31.USD","IE00B64PRP62.GBP","LU0006061336.USD","LU0211326839.USD","LU1201861249.SGD","LU0162691827.USD","GTLB","USAR","LU1267930227.SGD","BK4566","LU2361044865.SGD","IE00BFXG1179.USD","BX","BK4516","LU0208291251.USD","LU0211331839.USD","HIMZ","LU1244550221.USD","LU0265550946.USD","LU0048573561.USD","LU0251131958.USD","LU0320765489.SGD","M","IE0004445239.USD","BK4114","STLD","LU0106261372.USD","FDX","LU1989771016.USD","OLLI","BK4613","LDOS","LU1989764748.USD","IE00B66KJ199.SGD","COCP","MMED","THO","LU0130102774.USD","LU1935043536.SGD","KKR","LU1116320737.USD","IE00B7SZL793.SGD","LU1291159041.SGD","BK4007","TTI","IE00BQXX3C00.GBP","LU0432979614.USD","FDXF","HIMS","LU1668664300.SGD","LU1935042991.SGD","BK4099","BK4123","IE00B3QW5Z07.USD","LU1935042215.USD","LU2361045086.USD","HIMY","LU1670627923.USD","LU1244550494.USD","LU2461242641.AUD","IGME","BK4076","LU1116320901.HKD","LU2089284900.SGD","BK4198","LU1935043023.USD","LU0314106906.USD","LU0868494617.USD","HGV","IE000M9KFDE8.USD","CTMX","LU0158827948.USD","LU0971096721.USD","BK4141","IE00BN8TJ469.HKD","LU1983299246.USD","LU0310800965.SGD","LU2023251221.USD","LU1571399168.USD","LU0251142724.SGD","IE00BLSP4239.USD","LU1244550577.SGD","IE00B19Z4B17.USD","LU2089283258.USD","LU0976567544.SGD","LU1061106388.HKD","LU0742534661.SGD","AXSM","BK4505","HMYY","LU0122379950.USD","BK4097","LU0980610538.SGD","LU0314104364.USD","BK4103","TGTX","LU2271345857.HKD","LUNR","BK4187","IE00BLSP4452.SGD","BK4139","BK4533","BK4615","IE00B3T34201.USD","LU0265550359.USD","GMEY","BK4082","LU1363072403.SGD","BK4588","GMEU","LUNL","BK4096","IE00BBT3K403.USD","IE00BVYPNW00.USD","BK4196","IE00BQXX3D17.EUR","MDT","NRXP","OWL","IE00B42XCP33.USD","LU0072461881.USD","LU2112291526.USD","USAX","BK4168","HIYY","BK4142","TE","IE00BDGV0183.EUR","ARES","LU1791807156.HKD","LU2468319806.SGD","BK4577","LU1506573853.SGD","BK4220","BK4179","LU0128525689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640904990","title":"BUZZ-NRx Pharma dives on deep-discounted share offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640904990","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640904990?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:38","pubTimestamp":1780490296,"startTime":"0","endTime":"0","summary":"BUZZ-NRx Pharma dives on deep-discounted share offering** NRx Pharmaceuticals' NRXP.O shares down 21% to $3.65 before the bell as follow-on prices at steep discount** Biopharma focused on treatments for depression, chronic pain and PTSD announces ~5.7 mln shares at $3.50 for $20 mln gross proceeds** Offering price represents 24.2% discount to stock's last sale on Tues** Wilmington, Delaware-based NRXP has ~36.2 mln shares outstanding** Co intends to use net offering proceeds for working capital and to support growth** BTIG lead bookrunner, joined by Lucid Capital Markets** Through Tues close, NRXP stock surged 117% this quarter** All 5 analysts covering the stock rate it \"strong buy\" or \"buy\"; median PT $45, according to LSEG data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nL6N42B0SL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640767901","title":"NRx Pharmaceuticals prices 5,714,286-share follow-on at $3.5 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2640767901","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640767901?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:18","pubTimestamp":1780489128,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals priced an underwritten follow-on offering of 5,714,286 common shares at USD 3.5 each.Gross proceeds expected at about USD 20 million; up to USD 23 million if underwriters exercise a 30-day option for 857,142 shares.Closing expected June 4, 2026, subject to customary conditions.Net proceeds earmarked for working capital, general corporate purposes, growth support.BTIG named lead bookrunner; Lucid Capital Markets joint bookrunner.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL15BdLg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","BK4112","LU2210149790.SGD","LU0314104364.USD","BK4007","BK4588","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","NDAQ","SG9999014021.USD","IE00BN0W2V16.EUR","NRXP","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901763","title":"NRX Pharmaceuticals - Prices Public Offering of 5.71 Mln Shares at $3.5 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901763","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901763?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:18","pubTimestamp":1780489093,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA6FWD0H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640487909","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2640487909","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640487909?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:36","pubTimestamp":1780486588,"startTime":"0","endTime":"0","summary":"Jianzhi Education Technology  shares were down 41% in Wednesday premarket activity after the company's wholly owned subsidiary, Beijing Sentu Education Technology, entered a cooperation agreement with Shenzhen TaiDian Industry, adding to the previous session's 77% decline.Inotiv  stock was down 29% after the company said it has agreed to implement a recapitalization transaction with lenders and creditors.Wing Yip Food  shares were down 24%, following the previous session's 13% gain.Hitek Global  stock was down 21%, after a 91% decline in the earlier session.NRx Pharmaceuticals  shares were down 19%, after the company announced plans to launch a public offering of common shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4212","BK4121","BK4204","JZ","WYHG","NOTV","NRXP","BK4007","HKIT","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640218519","title":"Stocks to Watch: GameStop, GitLab, NRx Pharmaceuticals, Xos","url":"https://stock-news.laohu8.com/highlight/detail?id=2640218519","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640218519?lang=en_us&edition=fundamental","pubTime":"2026-06-03 06:46","pubTimestamp":1780440360,"startTime":"0","endTime":"0","summary":"GameStop reported a higher first-quarter profit and announced a $2 billion stock buyback authorization. Shares rose 6.5% to $22.28 in after-hours trading on Tuesday.GitLab said it would cut about 14% of its staff as part of a pivot toward artificial-intelligence. The stock fell 5.5% to $30.08 after the bell.NRx Pharmaceuticals proposed a public stock offering. Shares fell 20% to $3.70.Xos said it planned to launch a new series of power systems to support artificial-intelligence data-center energy needs. The stock surged 125% to $5.01.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4076","IGME","BK4007","GTLB","XOS","BK4097","BK4149","BK4547","BK4577","GMEY","GME","BK4613","NRXP","BK4607","BK4585","GMEU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640926455","title":"NRx Pharmaceuticals Shares Sink on Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640926455","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640926455?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:15","pubTimestamp":1780434900,"startTime":"0","endTime":"0","summary":"Shares of NRx Pharmaceuticals slid after the company proposed a public offering of its common stock.The stock retreated 19% to $3.74 after hours. Shares had gained 70% year-to-date when the market closed.The biopharmaceutical company said after the closing bell Tuesday that it intends to offer an unspecified number of shares. It would use the proceeds for working capital and general corporate purposes to support growth.NRx said it would grant the offering's underwriter a 30-day option to buy an additional 14% of the shares it sells during the offering.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"NRx Pharmaceuticals Shares Sink on Stock Offering","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640292315","title":"NRx Pharmaceuticals plans underwritten public offering of common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2640292315","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640292315?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:02","pubTimestamp":1780430554,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals launched an underwritten follow-on offering of common stock; deal size, pricing, timing not disclosed.Underwriters hold a 30-day option to buy up to 15% more shares on the same terms.Net proceeds earmarked for working capital, general corporate purposes, growth support.BTIG acting as lead bookrunner; Lucid Capital Markets serving as joint bookrunning manager.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL4wmDm4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","SG9999014021.USD","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014013.SGD","LU2210149790.SGD","IE00BN0W2W23.USD","NRXP","SG9999014039.USD","BK4585","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4007","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640923944","title":"NRX Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2640923944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640923944?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:01","pubTimestamp":1780430460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA71X7TL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667445","title":"NRx partner Emobot reports pooled clinical validation of EMOCARE depression monitoring tool at ASCP 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638667445?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:04","pubTimestamp":1779966299,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals flagged clinical validation results for Emobot Health’s EMOCARE depression monitoring tool, already presented at ASCP 2026.Pooled observational studies in adults with major depressive disorder or bipolar disorder showed EMOCARE broadly tracked clinician assessments of depression.Results also indicated the tool was responsive to changes in patient-reported symptoms across follow-up visits.NRx plans deployment across the Hope Therapeutics psychiatry clinic network to support between-visit monitoring and relapse detection.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL5n32tJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NRXP","BK4112","SG9999014039.USD","NDAQ","SG9999014013.SGD","IE00BN0W2W23.USD","LU0314104364.USD","BK4585","BK4007","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638957504","title":"NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System","url":"https://stock-news.laohu8.com/highlight/detail?id=2638957504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638957504?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301787/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Subsidiary-HOPE-Therapeutics-Becomes-First-Commercial-Site-to-Deploy-Zeta-Surgical-s-FDA-Cleared-Zeta-TMS-Navigation-System.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4585","BK4211","BK4588","NRXP","HOPE","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636655027","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2636655027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636655027?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:00","pubTimestamp":1779102000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA6JVMPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636935027","title":"Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2636935027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636935027?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:00","pubTimestamp":1779102000,"startTime":"0","endTime":"0","summary":"Key highlights from the first quarter of operations under the expanded management team include the following:. -- Anticipated FDA decision on the Company's ANDA for Preservative-Free. Ketamine in Q3 2026, with favorable preliminary determinations already. received from the FDA Office of Generic Drugs on bioequivalence, labeling,-- Initiation of commercial manufacturing of Ketamine at the 1 million dose. per month level with recent FDA inspection of the manufacturing facility. and granting of inspection status consistent with launch of an ANDA drug.-- Completed a Type C meeting with the FDA Division of Psychiatry Products. and CDER leadership, in which the Agency expressed openness to existing. clinical trial data and Real World Evidence supporting approval without. antibodies, cell lines, and Phase 2 data targeting HERVs implicated in. WILMINGTON, Del., May 18, 2026  -- NRx Pharmaceuticals, Inc.   a clinical-stage biopharmaceutical company, today announced financial results for the qua","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","TM","NQmain","LU1732799900.SGD","BK4604","LU0158827781.USD","BK4516","LU0006306889.USD","LU0314104364.USD","LU0106261372.USD","LU1988902786.USD","LU1244550577.SGD","LU0320765646.SGD","BK4504","LU1732800096.USD","LU2023251221.USD","BK4099","LU1668664300.SGD","LU1064131342.USD","LU0390134368.USD","BK4534","LU2111349929.HKD","LU0557290698.USD","LU0795875169.SGD","LU0528227936.USD","LU0971096721.USD","LU0106831901.USD","BK4232","LU0267386448.USD","LU0882574139.USD","LU1989772923.USD","LU1720051108.HKD","LU1791710582.SGD","LU1548497426.USD","R","BK4022","LU1989772840.SGD","03160","LU0053666078.USD","NRXP","BK4555","LU0225283273.USD","BK4585","BK4581","IE00BZ1G4Q59.USD","LU1162221912.USD","LU1363072403.SGD","IND","LU0234570918.USD","LU2271345857.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635537270","title":"NRX Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635537270","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635537270?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:08","pubTimestamp":1778882923,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryNRX Pharmaceuticals Inc NRXP.OQ reported a quarterly adjusted loss of 4 cents per share for the quarter ended M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S293:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635534650","title":"NRX Pharmaceuticals Q1 EPS $(0.04) Up From $(0.34) YoY, Sales $1.068M","url":"https://stock-news.laohu8.com/highlight/detail?id=2635534650","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635534650?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:55","pubTimestamp":1778882120,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 percent increase over losses of $(0.34) per share from the same period last year.  The company reported $1.068 million in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52619820/nrx-pharmaceuticals-q1-eps-0-04-up-from-0-34-yoy-sales-1-068m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NRX Pharmaceuticals Q1 EPS $(0.04) Up From $(0.34) YoY, Sales $1.068M","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":-0.0633},{"period":"1month","weight":0.3574},{"period":"3month","weight":1.4353},{"period":"6month","weight":0.7542},{"period":"1year","weight":0.4082},{"period":"ytd","weight":0.5277}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.074525},{"month":2,"riseRate":0.2,"avgChangeRate":-0.102766},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034339},{"month":4,"riseRate":0.4,"avgChangeRate":-0.100305},{"month":5,"riseRate":0.8,"avgChangeRate":0.153649},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.149434},{"month":7,"riseRate":0.4,"avgChangeRate":0.039708},{"month":8,"riseRate":0.2,"avgChangeRate":-0.14211},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012776},{"month":10,"riseRate":0.6,"avgChangeRate":0.037482},{"month":11,"riseRate":0.4,"avgChangeRate":0.048439},{"month":12,"riseRate":0.6,"avgChangeRate":0.121824}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}